ALNY FY 2014 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2014 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M+7.2% YoY

Gross Profit

$51M100.0% margin

Operating Income

-$405M-801.0% margin

Net Income

-$360M-712.8% margin

EPS (Diluted)

$-4.85

Cash Flow

Operating Cash Flow

-$166M

Free Cash Flow

-$175M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$143M

Stockholders' Equity

$936M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$47M	+7.2%
Gross Profit	$51M	$47M	+7.2%
Operating Income	-$405M	-$93M	-335.7%
Net Income	-$360M	-$89M	-303.9%